#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Fixed-dose combinations of antidiabetic drugs


Authors: M. Paclíková;  A. Šmahelová
Authors‘ workplace: Diabetologické centrum, III. interní geronto-metabolická klinika LF UK a FN Hradec Králové
Published in: Kardiol Rev Int Med 2016, 18(2): 104-108

Overview

Current guidelines from ADA (American Diabetes Association) and EASD (European Association for the Study of Diabetes) for the treatment of type 2 diabetes, underline individualisation of treatment, early start of combination therapy to hit more pathophysiological pathways, and consistent treatment of comorbidities. The fixed combinations of antidiabetic drugs provide good means to achieving these goals without increasing the number of tablets. This article presents an overview of the currently available fixed combinations of antidiabetic drugs, their importance in the treatment of type 2 diabetes, and considers the importance and the possibilities of influencing patients' adherence to treatment.

Keywords:
type 2 diabetes mellitus –  combination therapy –  fixed-dose combination –  adherence to the treatment


Sources

1. IDF diabetes atlas. 7th ed. Available from: http://www.diabetesatlas.org.

2. Novinky ÚZIS ČR. Činnost odboru diabetologie, péče o diabetiky v roce 2013. Dostupné z: http://www.uzis.cz/rychle-informace/cinnost-oboru-diabetologie-pece-diabetiky-roce-2013.

3. DeFronzo RA, Banting Lecture. From the Triumvirate to the omnious octet: new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773–795. doi: 10.2337/db09-9028.

4. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429–442. doi: 10.1007/s00125-014-3460-0.

5. Škrha J, Pelikánová T, Kvapil M. Doporučený postup péče o diabetes mellitus 2. typu, Česká diabetologická společnost, 2016. Dostupné z: http://www. diab.cz.

6. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 1218–1224.

7. Lavarnia F, Adkins S, Shubrook JH. Use of oral combination therapy for type 2 diabetes in primary care: meeting individualized patient goal. Postgrad Med 2015; 127: 808–817. doi: 10.1080/00325481.2015.1085293.

8. Šmahelová A. Význam kombinovaných perorálních antidiabetik v léčbě diabetu 2. typu. Interní Med 2009; 11: 155–158.

9. Šmahelová A. Pioglitazon – využití v léčbě diabetika 2. typu. Kapitoly z kardiologie 2013; 4: 122–125.

10. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470–512. doi: 10.1124/pr.108.000604.

11. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Praha: Mladá fronta 2011.

12. Šmahelová A. Gliptiny v léčbě diabetu 2. typu – současnost a budoucnost. Farmakoterapie 2011; 7: 462–467.

13. Kvapil M. Inhibitory SGLT2: nová cesta k léčbě diabetu. In: Kvapil M (ed). Diabetologie 2010. Praha: Triton 2010.

14. Asano T, Anai M, Sakoda H et al. SGLT as a therapeutic target. Drugs Fut 2004; 29: 461–466.

15. Kvapil M. Dapagliflozin. Farmakoterapie 2013; 9: 356–360.

16. Škrha J. Empagliflozin a současné postavení inhibitorů SGLT2 v terapii diabetu 2. typu. Farmakoterapie 2015; 11: 98–103.

17. Prázný M, Slíva J. Empagliflozin – nový inhibitor SGLT2 pro léčbu diabetu 2. typu. Farmakoterapie 2014; 10: 50–53.

18. Campbell JE, Drucker DJ. Pharmacology, physiology and mechanism of incretin hormone action. Cell Metab 2013; 17: 819–837. doi: 10.1016/j.cmet.2013.04.008.

19. Gough SC, Bode B, Woo V et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014; 2: 885–893. doi: 10.1016/S2213-8587(14)70174-3.

20. Russel-Jones D. Combination of insulin Degludec/liraglutid (IDegLira): key results from DUAL programme. EASD 2015. Available from: http://www.easdvirtualmeeting.org/resources/results-of-the-dual-programme.

21. J. Rosenstock. Benefits of fixed -ratio formulation of once -daily insulin glargine/lixisenatide (LixiLan) vs glargine in type 2 diabetes inadequately controlled on metformin. Oral Presentation. EASD 2014, Vídeň.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#